南方通信(01617.HK)擬折讓約17.22%配售2.46億股 籌資3000萬港元
格隆匯11月26日丨南方通信(01617.HK)發佈公吿,於2021年11月26日,配售代理與公司訂立配售協議,公司擬配售最多2.46億股,相當於現有已發行股份20.00%及經配發擴大後已發行股份約16.67%。配售價每股配售股份0.125港元,較股份於配售協議日期收市價每股0.151港元折讓約17.22%。
預期配售事項最高所得款項總額及所得款項淨額將分別為約3080萬港元及3000萬港元。配售事項所得款項淨額擬用作集團一般營運資金。
董事認為,配售事項可鞏固公司的財務狀況以作營運,併為公司提供資金以應付未來業務的任何投資機會。配售事項亦為拓展股東基礎及擴大公司資本基礎的良機。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.